Compounded vs. brand-name GLP-1: what is the difference?

Brand-name GLP-1 medications are FDA-approved products. Compounded versions are not FDA-approved, and Full Precision Health does not prescribe them, shortage exception or not. That single distinction, reviewed or not reviewed, is the thread the rest of this article pulls on.

If you have looked into GLP-1 medications in the last few years, you have almost certainly run into the word “compounded.” It shows up in ads, in Facebook groups, and in telehealth offers that look a lot cheaper than the brand name. The word itself is not scary. What it means for the medication you are injecting is worth understanding before you decide anything.

What compounding actually is

Compounding is the practice of a pharmacy mixing or altering a drug for an individual patient, rather than dispensing a mass-manufactured product exactly as it left the manufacturer. Compounding has a legitimate, long-standing role in medicine: a child who needs a liquid version of a tablet, a patient allergic to a dye or filler in the commercial product, a dosage strength that is not commercially available. That is what compounding pharmacies were built for.

Why compounded GLP-1s spread

GLP-1 medications became compounded at a much larger scale for a different reason: shortage. When manufacturer supply could not keep up with demand, federal rules allow compounding pharmacies to produce a version of a drug that is officially listed in shortage, as a stopgap. That shortage exception is what let an entire market of compounded semaglutide and tirzepatide grow so quickly. It was built for a supply gap, not as a permanent parallel product line.

Why the shortage exception does not mean permanent

Federal law treats the shortage exception as temporary by design. Once a manufacturer’s supply catches up and a medication is no longer listed in shortage, the legal basis for compounding a near-identical copy at scale is supposed to end with it. That created a strange period where compounded versions of popular GLP-1s remained widely marketed even as the underlying shortage designation moved, and enforcement caught up unevenly. It is a useful reminder that availability of a compounded offer is not the same as a clear, current legal basis for it.

The core difference: FDA approval

This is the part that matters most. A brand-name GLP-1 is FDA-approved: the exact formulation, manufacturing process, and dosing went through FDA review for safety and effectiveness before it reached a pharmacy shelf. A compounded version has not. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety or effectiveness. That does not automatically mean a compounded product is unsafe, but it does mean nobody outside the compounding pharmacy has verified its potency, purity, or consistency from batch to batch the way the FDA verifies a brand-name drug.

Where Full Precision Health lands

Our medical program prescribes brand-name GLP-1 medications only. We do not use compounded versions, shortage exception or not. When a patient’s insurance covers a brand-name GLP-1, we pursue prior authorization on their behalf and handle the appeals if a plan denies or delays. When insurance does not cover it or a gap remains, the fallback is a manufacturer direct-pay program, such as LillyDirect or NovoCare, not a compounding shortcut. You can read the full reasoning on our standards page.

What to ask before you commit to any offer

If a telehealth offer for a GLP-1 medication looks unusually accessible, it is worth asking directly whether the product is FDA-approved brand-name or a compounded version, and whether a licensed medical provider evaluated you before prescribing. Those two questions cut through most of the marketing language in this category.

Wegovy and Zepbound are trademarks of their respective manufacturers, referenced here for education, not endorsement. This article is general information, not medical advice, and does not describe pricing for any specific patient.